The Ministry of Health has identified and prioritized Clinical Extremely Vulnerable (CEV) populations to book appointments to receive COVID-19 vaccinations starting March 29, 2021.
Newsroom
All COVID-19 vaccines approved by health Canada for use in Canada, including the AstraZeneca/COVISHIELD vaccine are considered to be very safe products. A normal part of any vaccine rollout is careful monitoring of serious side effects or adverse events that may be associated with its use.
The shortage of tobramycin 0.3% ophthalmic ointment X 3.5 gram tubes has resolved and NH pharmacy now has access to an adequate ongoing supply.
Sodium phosphate 3 mmol/mL injection is currently available in limited quantities only. NH has approximately 3 to 4 weeks of supply between current pharmacy stock and stock available in patient care areas.
Anticipated Availability: early May 2021
The shortage of metoclopramide 5 mg/mL X 2 mL injectable has resolved and NH pharmacy now has access to an adequate ongoing supply.
The shortage of erythromycin 5 mg/g ophthalmic ointment X 1 gram tubes has resolved and NH pharmacy now has access to an adequate ongoing supply.
BC Diagnosis Codes (BCDX) were implemented to establish patient prioritization and wait time targets across BC.